DAXXIFY

DAXXIFY™ is FDA approved to help smooth moderate to severe lines between the brows. It is the only long-lasting frown line treatment powered by a peptide with results that last on average 6 months and up to 9 months for some.*The active ingredient in DAXXIFY™ is a purified protein called botulinum toxin type A.*At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Between 3% and 5% of patients in clinical studies had no or minor frown lines 9 months after treatment. In other safety studies, between 5% and 17% of patients still had noticeable improvement 9 months later.

Injectable wrinkle treatments containing botulinum toxin type A have been used to improve the look of moderate to severe frown lines for more than 20 years. The first FDA-approved treatment was BOTOX® Cosmetic, followed by Dysport®, Xeomin®, and Jeuveau®.

Although today’s wrinkle reducers all contain botulinum toxin type A, it’s important to know that no two treatments are alike and the doses cannot be interchanged with each other.

DAXXIFY™ is the only long-lasting frown line treatment powered by a peptide. Results last on average 6 months and up to 9 months for some.^†

All frown line treatments require a special ingredient to stabilize botulinum toxin A, the protein responsible for helping smooth moderate to severe frown lines. For instance, BOTOX® Cosmetic uses human serum albumin (HSA), a blood product, as its stabilizer. Dysport®, another frown line treatment, uses HSA as a stabilizer and cow’s milk protein as a protectant.

DAXXIFY™ is unique because it is the only formulation that uses a novel peptide as a stabilizer and does not contain human or animal byproducts.

^†At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Between 3% and 5% of patients in clinical studies had no or minor frown lines 9 months after treatment. In other safety studies, between 5% and 17% of patients still had noticeable improvement 9 months later.

In short, no, and here’s why. Units are like fingerprints—they are a proprietary measurement of a treatment’s unique potency.

Because of the differences in how treatments are formulated and tested, you cannot compare or convert Units between them, just like you cannot compare 2 fingerprints.

A clearer way to understand dosing is to look at how many nanograms of active ingredient (botulinum toxin type A) a product has.

Double the Units does not mean double the dose

DAXXIFY™Approved frown line dose: 40 Units
Amount of active ingredient: 0.18 nanograms

BOTOX® CosmeticApproved frown line dose: 20 Units
Amount of active ingredient: 0.18 nanograms

DYSPORT®Approved frown line dose: 50 Units
Amount of active ingredient: 0.27 nanograms

As you can see, despite the number of Units, DAXXIFY™ isn’t 2x the dose of BOTOX® Cosmetic, nor is Dysport® 2.5x the dose of BOTOX® Cosmetic. Talk to your provider about DAXXIFY™ and your aesthetic goals.

All frown line treatments require a special ingredient to stabilize botulinum toxin A, the protein responsible for helping smooth moderate to severe frown lines. For instance, BOTOX® Cosmetic uses human serum albumin (HSA), a blood product, as its stabilizer. Dysport®, another frown line treatment, uses cow’s milk protein in addition to HSA.

DAXXIFY™ is unique because it is the only formulation that uses a novel peptide as a stabilizer and does not contain human or animal byproducts.

DAXXIFY™ was studied in the largest-ever clinical study for a frown line treatment and included more than 2,800 people across different ages and skin types. Here are some things you should know about DAXXIFY™:

• There were no serious treatment-related side effects
• The active ingredient in DAXXIFY™ is botulinum toxin type A, an ingredient that has been used in frown line treatments for more than 20 years
• 96% of people treated with DAXXIFY™ were satisfied with their results^‡

^‡96% of patients reported they were satisfied on a 7-point scale when evaluated at 4 weeks in clinical studies.

No, not necessarily. The most common side effects observed in clinical trials occurred within one to two weeks after injection and lasted only a short while. This is consistent with other frown line treatments.

DAXXIFY™ is well-studied, with no serious treatment-related side effects seen in large-scale clinical trials.

If you’re like most people, you probably get a frown line treatment around twice a year. But here’s the thing: conventional treatments only last 3–4 months. That means you may spend the next 2-3 months of the year with those frown lines staring back at you between treatments. That’s up to 4-6 months of total wear off time per year!

DAXXIFY™ is different. With those same 2 treatment visits, you can keep your frown lines smoother for a full year!^§

^§At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment.

DAXXIFY™ minimizes the appearance of moderate to severe frown lines by temporarily relaxing the underlying muscles that cause these wrinkles. DAXXIFY™ is a long-lasting botulinum toxin type A treatment with a novel peptide.

Facial fillers, also known as dermal fillers, are typically made of hyaluronic acid and are used to add volume, fullness, and structure to areas of the face. They can help contour cheekbones, soften lines around the nose and mouth, and volumize lips. Dermal fillers target volume loss rather than muscle-related wrinkles.

You may see results with DAXXIFY™ as early as the next day after treatment, and typically within two days.

Is your frown line treatment not lasting as long as you would like? If so, DAXXIFY™ could be the solution for you. Discuss your treatment goals with your aesthetic services provider.

Botulinum toxins are biologics, produced from a bacterium called Clostridium botulinum. They are used to inhibit the transmission of specific chemical signals from nerves, primarily those signals that cause muscular contractions. Botulinum toxin type A injections temporarily relax the facial muscles that cause wrinkles between the brows, reducing their appearance.

DAXXIFY™ is the only FDA-approved, long-lasting frown line treatment (neuromodulator) to help smooth moderate to severe lines between the brows, lasting on average 6 months and up to 9 months in some.^¶

Injections of specific botulinum toxin formulations are also utilized in the treatment of medical conditions.

^¶At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Between 3% and 5% of patients in clinical studies had no or minor frown lines 9 months after treatment. In other safety studies, between 5% and 17% of patients still had noticeable improvement 9 months later.

The safety and efficacy of DAXXIFY™ is well established, with more than 20 years of research. In fact, DAXXIFY™ has been studied in the largest ever phase 3 clinical trial program conducted for a frown line treatment and included more than 2,400 people across different ages and with different skin types. There were no notable differences in how DAXXIFY™ performed in clinical trial patients with varying skin types.

You may see results with DAXXIFY™ as early as the next day after treatment, and typically within two days. You should see noticeable results within a two-week time frame. You may experience mild injection-related bruising. In most cases, bruising heals within a few days after injection.

Ask your aesthetic provider for pre-treatment instructions prior to your DAXXIFY™ appointment.

A list of common avoidances before treatment include, but are not limited to:

• Retin-A
• Blood thinners
• Muscle relaxants
• Fish or oils rich in omega 3
• Allergy medication
• Topical steroids
• Sleep medications and supplements
• Aspirin
• St. John’s Wort
• Supplements containing Vitamin E
• Ibuprofen

DAXXIFY™ injections are typically performed with a small needle and people treated with frown line treatments say the injection feels like a pinch.

If you are concerned about discomfort, talk to your injector about options for minimizing pain, such as icing the area or applying a topical numbing cream. Treatment with DAXXIFY™ requires minimal downtime, and you can return to your daily routine immediately after your appointment.

There is a possibility that the area around the injection site will swell, turn red, and cause pain or tenderness from the injection itself; however, these side effects are typically very minor and go away after a few hours or days.

Several factors contribute to the formation of facial lines. Decreased collagen production, cellular changes, genetics, environmental damage, and sun damage may all play a role.

Facial lines are also formed by repeated muscle contractions such as frowning, squinting, or raising the eyebrows. These facial expressions cause the skin to furrow and fold, which eventually leads to the formation of wrinkles.

DAXXIFY™ works below the skin’s surface to temporarily reduce the underlying muscle activity responsible for moderate to severe frown lines.

DAXXIFY™ is manufactured in California, and the only prescription frown line treatment made in the United States. Conventional frown line treatments are manufactured in other countries, then imported into the United States.

In 2002, physicians and entrepreneurs founded a start-up in Silicon Valley, California to explore the use of peptides in biologics for different therapeutic uses. Their goal was to utilize peptides to transport biologics, typically large molecules, through the skin.

The initial idea was to formulate botulinum toxin type A, the active ingredient in DAXXIFY™, with a peptide to see if it could be applied topically to the skin to treat crow’s feet wrinkles. Through this process, scientists discovered that the formulation was optimally administered through injection. Several clinical studies were created to determine the correct dose for an injectable product that would treat frown lines.

In clinical studies, DAXXIFY™ lasted on average 6 months and up to 9 months for some people.* It is the only treatment of its kind formulated with a peptide.

*At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Between 3% and 5% of patients in clinical studies had no or minor frown lines 9 months after treatment. In other safety studies, between 5% and 17% of patients still had noticeable improvement 9 months later.